Equities

Japan Tissue Engineering Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
7774:TYO

Japan Tissue Engineering Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)601.00
  • Today's Change11.00 / 1.86%
  • Shares traded95.80k
  • 1 Year change+25.47%
  • Beta0.4044
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.

  • Revenue in JPY (TTM)2.26bn
  • Net income in JPY-461.45m
  • Incorporated1999
  • Employees204.00
  • Location
    Japan Tissue Engineering Co Ltd6-209-1, Miyakita-doriGAMAGORI-SHI 443-0022JapanJPN
  • Phone+81 533662020
  • Fax+81 533662019
  • Websitehttp://www.jpte.co.jp
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Japan Medical Dynamic Marketing Inc24.58bn-1.05bn13.18bn538.00--0.522424.420.5363-40.02-40.02933.26953.320.72020.63684.3445,695,190.00-3.134.27-3.804.9459.9365.20-4.355.781.2812.480.180228.508.356.79-136.31---1.378.45
OLBA Healthcare Holdings Inc124.48bn1.43bn13.22bn1.39k8.771.056.330.1062241.07241.0721,003.792,008.322.7716.234.8089,362,800.003.173.439.9111.3911.2611.491.151.220.958266.630.225530.513.492.61-4.6834.3828.7114.87
DVx Inc55.33bn308.75m13.28bn334.0041.821.4812.290.2429.4629.465,278.63831.732.2417.684.12165,663,400.001.252.643.286.459.6011.080.5581.281.23--0.002563.099.752.42137.18-12.33-2.4315.81
Daiken Medical Co Ltd10.17bn981.12m15.28bn180.0014.051.7912.441.5034.1534.15353.89267.890.90354.563.6456,482,360.008.727.8611.8311.2538.7941.239.659.511.89183.100.193969.412.073.1511.035.01-0.18892.83
Seed Co Ltd33.57bn1.17bn16.25bn985.0013.850.87483.660.484238.7638.761,109.07613.830.642.357.4334,078,080.002.222.313.583.9445.1242.203.473.300.59286.620.575736.012.580.8892-44.3833.9912.644.56
Hoshi Iryo-Sanki Co Ltd15.45bn1.45bn17.17bn500.0010.830.812410.421.11463.58463.584,949.106,178.920.626224.075.8130,904,100.005.886.007.197.6149.7248.989.399.193.09--0.0015.312.196.784.2114.77-18.276.96
Medius Holdings Co Ltd295.20bn1.36bn18.66bn2.61k13.780.92024.910.063260.8660.8613,250.33911.802.3918.174.56112,928,700.001.101.654.356.0311.8212.070.45960.64920.924313.810.587328.5711.126.5322.307.6516.287.39
Techno Medica Co Ltd10.70bn1.04bn22.65bn244.0017.271.2419.952.12149.78149.781,542.982,077.510.64062.173.6943,841,880.006.226.587.167.7947.6849.669.7112.305.99--0.0040.22-3.680.1936-25.480.0825-40.566.77
Japan Tissue Engineering Co., Ltd.2.26bn-461.45m23.96bn204.00--4.55--10.61-11.36-11.3655.62129.740.36614.015.6311,071,850.00-7.48-4.87-8.33-5.5159.6259.41-20.43-15.896.59--0.00---2.341.23-278.32--0.5717--
Findex Inc5.90bn1.18bn24.53bn311.0019.874.3116.304.1646.3946.39232.45214.020.94678.734.9918,984,330.0019.2116.4821.5419.1963.7758.1820.2916.354.18--0.0034.7312.516.419.7518.41-4.0213.40
Kusurinomadoguchi Inc11.58bn3.10bn30.04bn484.009.643.156.602.59274.21274.211,023.48838.470.7189--3.1923,926,840.0019.64--34.71--56.56--27.32------0.0872--28.41--133.66------
Mizuho Medy Co Ltd9.67bn2.81bn34.44bn187.0012.252.0411.233.56147.57147.57507.44884.420.49991.172.8851,689,840.0014.5429.3716.0335.7568.7374.8529.0935.778.01--0.0037.844.0012.20-0.032833.97-17.0647.14
Data as of Feb 13 2026. Currency figures normalised to Japan Tissue Engineering Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.11%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 08 Jan 202635.80k0.09%
Sawakami Asset Management, Inc.as of 31 Oct 20256.20k0.02%
LGT Capital Partners AG (Investment Management)as of 31 May 2025800.000.00%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2025200.000.00%
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.